Literature DB >> 4591176

Receptor for soluble C3 and C3b on human lymphoblastoid (RAJI) cells. Properties and biologocal significance.

A N Theofilopoulos, V A Bokisch, F J Dixon.   

Abstract

This study describes the presence of a receptor for fluid phase human C3 and C3b on Raji cell membranes. The binding of C3 and C3b was demonstrated indirectly by a fluoresceinated anti-C3 serum and directly by using radioiodinated proteins. No other complement proteins or serum factors were needed to mediate binding of C3 and C3b to the receptor. The possibility of enzymatic cleavage of C3 before or after its attachment on the cell membrane was ruled out by the demonstration of antigenically intact C3 on Raji cells. Inhibition and dissociation of Raji cell-EAC1423 rosettes by C3 and C3b indicated that both of these proteins bind to the same receptor site or closely associated receptor sites on Raji cells. C3b-bearing Raji cells were immune adherence negative, indicating that C3b binding to the receptor is brought about through the immune adherence region of the molecule and not the C3d portion. The C3 receptor on Raji cell membranes is uniformly distributed and can move on the membrane plane. Approximately 4 x 10(5) molecules of C3 or C3b bind per Raji cell. The receptor had a higher affinity for C3 than C3b, as was shown by uptake experiments and inhibition of Raji cell-EAC1423 rosette formation. Apart from the described receptor for C3 and C3b another specific receptor for C3b inactivator-cleaved C3b (C3d) bound to red cells was shown to be present on Raji cells. Raji cells cultured in medium containing fresh normal human serum and cobra venom factor were lysed. Similar results were obtained when C3b-bearing Raji cells were cultured in medium with fresh normal human serum. The lytic effect could be abolished by inactivating serum C3 proactivator (C3PA) and required C6. It was concluded that C3b bound to the Raji cell membrane activates the complement system through the alternate pathway and results in membrane damage and cytolysis. It is postulated that cell destruction by this mechanism may play an important role in vivo in controlling cell growth.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4591176      PMCID: PMC2139545          DOI: 10.1084/jem.139.3.696

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  31 in total

1.  A DIALYSIS TECHNIQUE FOR PREPARING FLUORESCENT ANTIBODY.

Authors:  H F CLARK; C C SHEPARD
Journal:  Virology       Date:  1963-08       Impact factor: 3.616

2.  A new method for preparing buffy coat-poor blood.

Authors:  T J GREENWALT; M GAJEWSKI; J L McKENNA
Journal:  Transfusion       Date:  1962 Jul-Aug       Impact factor: 3.157

3.  The immune-adherence phenomenon; an immunologically specific reaction between microorganisms and erythrocytes leading to enhanced phagocytosis.

Authors:  R A NELSON
Journal:  Science       Date:  1953-12-18       Impact factor: 47.728

4.  Growth and antigenic properties of a biopsy-derived Burkitt's lymphoma in thymus-less (nude) mice.

Authors:  C O Povlsen; P J Fialkow; E Klein; G Klein; J Rygaard; F Wiener
Journal:  Int J Cancer       Date:  1973-01-15       Impact factor: 7.396

5.  Hypothesis. Bound C3 as the second signal for B-cell activation.

Authors:  P Dukor; K U Hartmann
Journal:  Cell Immunol       Date:  1973-06       Impact factor: 4.868

6.  Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines.

Authors:  E Klein; G Klein; J S Nadkarni; J J Nadkarni; H Wigzell; P Clifford
Journal:  Cancer Res       Date:  1968-07       Impact factor: 12.701

7.  Human lymphoblastoid lines from lymph node and spleen.

Authors:  J A Levy; M Virolainen; V Defendi
Journal:  Cancer       Date:  1968-09       Impact factor: 6.860

8.  Two different complement receptors on human lymphocytes. One specific for C3b and one specific for C3b inactivator-cleaved C3b.

Authors:  G D Ross; M J Polley; E M Rabellino; H M Grey
Journal:  J Exp Med       Date:  1973-10-01       Impact factor: 14.307

9.  ISOLATION OF BETA IF-GLOBULIN FROM HUMAN SERUM AND ITS CHARACTERIZATION AS THE FIFTH COMPONENT OF COMPLEMENT.

Authors:  U R NILSSON; H J MUELLER-EBERHARD
Journal:  J Exp Med       Date:  1965-08-01       Impact factor: 14.307

10.  ISOLATION AND DESCRIPTION OF THE FOURTH COMPONENT OF HUMAN COMPLEMENT.

Authors:  H J MUELLER-EBERHARD; C E BIRO
Journal:  J Exp Med       Date:  1963-09-01       Impact factor: 14.307

View more
  29 in total

1.  Chemotactic activity derived from interaction of factors D and B of the properdin pathway with cobra venom factor or C3B.

Authors:  S Ruddy; K F Austen; E J Goetzl
Journal:  J Clin Invest       Date:  1975-03       Impact factor: 14.808

2.  Complement bridges between cells analysis of a possible cell-cell interaction mechanism.

Authors:  M P Dierich; B Landen
Journal:  J Exp Med       Date:  1977-12-01       Impact factor: 14.307

3.  Lymphocyte binding of fluid phase mouse C3b.

Authors:  M Papamichail; M B Pepys
Journal:  Immunology       Date:  1979-03       Impact factor: 7.397

Review 4.  Immune complexes in human diseases: a review.

Authors:  A N Theofilopoulos; F J Dixon
Journal:  Am J Pathol       Date:  1980-08       Impact factor: 4.307

Review 5.  Pitfalls in the methodology for detection of immune complexes.

Authors:  R Heimer; S Per
Journal:  Surv Immunol Res       Date:  1982

Review 6.  Factors influencing immune complex localisation.

Authors:  L Schrieber; R Penny
Journal:  Rheumatol Int       Date:  1984       Impact factor: 2.631

7.  Enzymic assay of C3b receptor on intact cells and solubilized cells.

Authors:  E Sim; R B Sim
Journal:  Biochem J       Date:  1983-02-15       Impact factor: 3.857

8.  Solubilization of an activity regulating C3b function from Raji cell membranes.

Authors:  P Carlson; S Ruddy; D H Conrad
Journal:  Immunology       Date:  1982-05       Impact factor: 7.397

9.  Complement-dependent cellular cytotoxicity: lymphoblastoid lines that activate complement component 3 (C3) and express C3 receptors have increased sensitivity to lymphocyte-mediated lysis in the presence of fresh human serum.

Authors:  O F Ramos; G Sármay; E Klein; E Yefenof; J Gergely
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

10.  Quantitative studies of the interaction of 3H-dsDNA/anti-DNA immune complexes with complement: comparison and evaluation of the Raji cell, the solution phase C1Q, and the red blood cell linked complement fixation radioimmunoassays.

Authors:  R P Taylor; B S Andrews; K W Morley; T Conlon
Journal:  Rheumatol Int       Date:  1981       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.